SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

HDFC is currently trading at Rs. 643.25, up by 4.45 points or 0.70% from its previous closing of Rs. 638.80 on the BSE.

The scrip opened at Rs. 640.80 and has touched a high and low of Rs. 648.40 and Rs. 638.30 respectively. So far 29667 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 780.05 on 17-Sep-2010 and a 52 week low of Rs. 582.25 on 09-Feb-2011.

Last one week high and low of the scrip stood at Rs. 679.65 and Rs. 628.00 respectively. The current market cap of the company is Rs. 93931.52 crore.

The Institutional holding in the company stood at 87.38% while Non-Institutions held 12.62%. 

HDFC Trustee Company have picked 5.01% stake in Aurobindo Pharma for its different funds. The trustee company have purchased 145,93,640 equity shares amounting to 5.01% of the paid up equity share capital. The purchase was carried out in open market and the company did not provide the value of the acquisition.

The different funds of HDFC Trustee Company which bought stake in Aurobindo Pharma include, HDFC arbitrage fund, HDFC balanced fund, HDFC equity fund, HDFC prudence fund, HDFC top 200 fund and HDFC mid cap opportunities.

Aurobindo Pharma headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.

The Company has reported a net loss of Rs 101.58 crore for the quarter ended June 30, 2011 as compared to net profit of Rs 63.34 crore for the quarter ended June 30, 2010. The company’s total income registered growth of 18.77% at Rs 1031.87 crore for the June quarter of FY12  from Rs 868.81 crore for the June quarter of the previous Fiscal.

HDFC-Amalgamated Share Price

2729.95 0.00 (0.00%)
12-Jul-2023 18:01 View Price Chart
Peers

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×